Viewing Study NCT00511459

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 2:44 PM
Ignite Modification Date: 2026-02-25 @ 8:11 PM
Study NCT ID: NCT00511459
Status: COMPLETED
Last Update Posted: 2015-10-29
First Post: 2007-08-02
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
Sponsor: Amgen
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Locally Recurrent and Metastatic Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Randomized View
None 4-Arm View
None Placebo controlled View
None Phase 2 Trial View
None AMG 386 View
None Paclitaxel View
None Bevacizumab View
None First-line Therapy View
None Her-2 Negative View
None Metastatic or Locally Recurrent Breast Cancer View